Currently, cancer antigen 125 (CA-125) represents the principle ovarian cancer biomarker; however, while it carries utility in assessing for cancer resurgence or tracking chemotherapy efficacy, it represents a poor screening tool, detecting approximately 50% of patients with stage I ovarian cancer. This evidence concerns the gene MUC16 and ovarian carcinoma.